HC Wainwright Issues Pessimistic Outlook for Savara Earnings

Savara Inc. (NASDAQ:SVRA) – Research analysts at HC Wainwright decreased their Q2 2026 earnings per share estimates for shares of Savara in a research note issued on Thursday, May 14th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.14). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Savara’s Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.34) EPS, FY2028 earnings at ($0.04) EPS, FY2029 earnings at $0.11 EPS and FY2030 earnings at $0.39 EPS.

A number of other research firms also recently commented on SVRA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Oppenheimer initiated coverage on Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 target price on the stock. William Blair set a $10.00 target price on Savara in a report on Monday, March 16th. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Savara presently has an average rating of “Moderate Buy” and an average price target of $9.13.

Savara Stock Down 2.4%

SVRA stock opened at $4.91 on Tuesday. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -8.77 and a beta of 0.28. The business’s fifty day moving average price is $5.34 and its two-hundred day moving average price is $5.49. Savara has a fifty-two week low of $1.89 and a fifty-two week high of $7.01. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.01).

Hedge Funds Weigh In On Savara

A number of institutional investors have recently modified their holdings of SVRA. Polar Capital Holdings Plc acquired a new position in shares of Savara during the fourth quarter worth approximately $50,086,000. RTW Investments LP acquired a new position in shares of Savara during the fourth quarter worth approximately $35,893,000. VR Adviser LLC raised its position in shares of Savara by 172.7% during the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares during the period. Marshall Wace LLP bought a new position in shares of Savara during the 4th quarter worth approximately $27,496,000. Finally, Spruce Street Capital LP bought a new position in shares of Savara during the 4th quarter worth approximately $14,539,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.